tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

FATE Stock Latest News

Fate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
Company AnnouncementsFate Therapeutics Faces Nasdaq Delisting Risk: Implications for Investors
10d ago
FATE
Fate Therapeutics Reports Q2 2025 Financial Results
PremiumCompany Announcements
Fate Therapeutics Reports Q2 2025 Financial Results
10d ago
FATE
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
PremiumThe Fly
Fate Therapeutics price target lowered to $2.50 from $4 at Wells Fargo
11d ago
FATE
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
PremiumRatings
Cautious Hold Rating for Fate Therapeutics Amid Developmental and Regulatory Uncertainties
11d ago
FATE
Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials
PremiumRatings
Cautious Hold Rating on Fate Therapeutics Amid Promising CAR-iT Developments and Early Stage Trials
11d ago
FATE
Fate Therapeutics Announces Corporate Restructuring Plan
PremiumCompany AnnouncementsFate Therapeutics Announces Corporate Restructuring Plan
11d ago
8K
FATE
Fate Therapeutics reports Q2 EPS (29c), consensus (34c)
Premium
The Fly
Fate Therapeutics reports Q2 EPS (29c), consensus (34c)
11d ago
FATE
Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases
Premium
Company Announcements
Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases
22d ago
FATE
Cautious Outlook on Fate Therapeutics Amid Promising Data and Safety Concerns
PremiumRatings
Cautious Outlook on Fate Therapeutics Amid Promising Data and Safety Concerns
2M ago
FATE
Cautious Hold on Fate Therapeutics: Promising Early Data for FT819 in Lupus, Awaiting Broader Evidence
PremiumRatings
Cautious Hold on Fate Therapeutics: Promising Early Data for FT819 in Lupus, Awaiting Broader Evidence
2M ago
FATE
Cautious Hold Rating on Fate Therapeutics Amid Promising but Preliminary CAR-T Therapy Data
PremiumRatings
Cautious Hold Rating on Fate Therapeutics Amid Promising but Preliminary CAR-T Therapy Data
2M ago
FATE
Fate Therapeutics announces updated data for FT819
PremiumThe Fly
Fate Therapeutics announces updated data for FT819
2M ago
FATE
Fate Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany AnnouncementsFate Therapeutics Approves Key Proposals at Annual Meeting
3M ago
8K
FATE
Fate Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Fate Therapeutics Reports Q1 2025 Financial Results
3M ago
FATE
Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion
Premium
Ratings
Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion
3M ago
FATE
Fate Therapeutics price target lowered to $4 from $5 at Baird
PremiumThe Fly
Fate Therapeutics price target lowered to $4 from $5 at Baird
3M ago
FATE
Fate Therapeutics price target lowered to $2 from $10 at Barclays
PremiumThe Fly
Fate Therapeutics price target lowered to $2 from $10 at Barclays
3M ago
FATE
Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
PremiumRatings
Cautious Optimism for Fate Therapeutics Amid Promising Developments and Financial Stability
3M ago
FATE
Fate Therapeutics reports Q1 EPS (32c), consensus (38c)
PremiumThe Fly
Fate Therapeutics reports Q1 EPS (32c), consensus (38c)
3M ago
FATE
FATE Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsFATE Upcoming Earnings Report: What to Expect?
4M ago
FATE
Fate Therapeutics receives RMAT designation from FDA for FT819
Premium
The Fly
Fate Therapeutics receives RMAT designation from FDA for FT819
4M ago
FATE
Hold Rating for Fate Therapeutics Amid Promising FT819 Developments and Ongoing Uncertainties
Premium
Ratings
Hold Rating for Fate Therapeutics Amid Promising FT819 Developments and Ongoing Uncertainties
5M ago
FATE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >